Crinetics® Pharmaceuticals

August 7, 2025

Second Quarter 2025 Financial Results and Business Update

Safe Harbor Statement

This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," "us," or "our") cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: the plans and timelines for the FDA and EMA responses to regulatory filings and the commercial launch of paltusotine, if approved; the Company's ability to successfully launch paltusotine and address unmet need among people with acromegaly; the expected timing of patient enrollment in the Phase 3 program of paltusotine for carcinoid syndrome; the expected timing of patient enrollment in additional studies of atumelnant in CAH or our plans or timing for a phase 2/3 study of atumelnant in Cushing's syndrome; the plans and timelines for the clinical development of our drug candidates, including the therapeutic potential and clinical benefits or safety profile thereof; and expected timing for the initiation of clinical trials for our nonpeptide drug conjugate development candidate (CRN09682); or the filing of INDs for our PTH antagonist, TSH antagonist, SST3 agonist, or the potential benefits of our development candidates in patients across multiple indications or the expected timing of the advancement of those programs; the expected timing of additional research pipeline updates; and the company's anticipated cash runway or its operating cash burn guidance. In some cases, you can identify forward-looking statements by terms such as "may," "believe," "anticipate," "could," "should," "estimate," "expect," "intend," "plan," "project," "will," "contemplate," "predict," "continue," "forecast," "aspire," "lead to," "designed to," "goal," "aim," "potential," "target," or other similar terms or the negatives thereof.

These statements speak only as of the date of this presentation, involve known and unknown risks, uncertainties, assumptions, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, without limitation: data that we report may change following a more comprehensive review of the data related to the clinical studies and, as more patient data become available, such data may not accurately or completely reflect the results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; the possibility of unfavorable new clinical data and further analyses of existing clinical data; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; our dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of our clinical trials and nonclinical studies; regulatory developments or political changes, including policies related to pricing and pharmaceutical drug reimbursement in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization; our ability to obtain and maintain intellectual property protection for our product candidates; we may use our capital resources sooner than we expect or our cash burn rate may accelerate; and other risks described under the heading "Risk Factors" in documents we file from time to time with the Securities and Exchange Commission. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Crinetics Pharmaceuticals

Serving Our Patients

Our mission is to build the world's leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives.

We made a **commitment** to the acromegaly community
And we stand by it

Traci
Acromegaly Patient

Coming Soon – PDUFA Date September 25, 2025

Once-Daily Oral

Palsonify™

(paltusotine) tablets

PALSONIFY (paltusotine) is an investigational drug. Commercial launch of paltusotine is dependent on regulatory approval.

Crinetics Pharmaceuticals

Engaging with Healthcare Professionals Across Multiple Platforms

Increasing Education and Awareness

- ✓ MSLs in the field **visiting endocrinologists**
- ✓ Evidence generation and **new publications** in progress
- ✓ Strong presence at **medical congresses**

19th International Pituitary Congress — July 9 – 11, 2025 — San Francisco, California

AACE American Association of Clinical Endocrinology

Long-Term Data Positively Received by HCPs

- ✓ **PALSONIFY** was **well-tolerated and IGF-1 levels** remained **stably controlled** during long-term PATHFNDR-1 and PATHFNDR-2 OLEs
- ✓ **Reductions in** patient-reported **symptom burden**, including severity and rates of symptom flares

PATHFNDR-1 — Paltusotine Acromegaly Therapy Featuring a Non-Invasive Daily Regimen

pathfndr-2 — Paltusotine Acromegaly Therapy Featuring a Non-Invasive Daily Regimen

"Coming Soon" Campaign Now Live

5 PALSONIFY (paltusotine) is an investigational drug. Commercial launch of PALSONIFY is dependent on regulatory approval
HCP: Healthcare practitioner; MSL: Medical Science Liaison; OLE: Open Label Extension.

Crinetics Pharmaceuticals

Preparing for a Successful Launch of PALSONIFY

ACTIVATE

ADOPT

ACCESS

ADHERE

Building Strong Foundational Infrastructure

…for paltusotine and the pipeline in the US and globally

- ✓ **Field force** on board
- ✓ Productive ongoing **engagement with payers**
- ✓ **Market research** and **ad boards** with patients, HCPs and payers
- ✓ Long-standing partnerships with **patient advocacy** organizations

PALSONIFY (paltusotine) is an investigational drug. Commercial launch of PALSONIFY is dependent on regulatory approval
HCP: Healthcare practitioner; MSL: Medical Science Liaison; OLE: Open Label Extension.

Crinetics Pharmaceuticals

Strategies to Address the Significant Unmet Need in the Acromegaly Community

~11,000
Addressable US patients

- **Currently on SRL Treatment** → Reduce burden and improve control
- **Undertreated** → Drive treatment to target
- **Untreated** → Educate and motivate

~500
Addressable US patients

- **Newly Diagnosed** → Initiate on innovative treatment

>17,000
US patients
5+ years to diagnose

- **Undiagnosed** → Find and treat

Once-Daily Oral
Palsonify™
(paltusotine) tablets

PDUFA Date of September 25, 2025

PALSONIFY (paltusotine) is an investigational drug. Commercial launch of paltusotine is dependent on regulatory approval.

Crinetics Pharmaceuticals

Mutli-Channel Approach Driving Patient Awareness

Educating and Empowering to Optimize Success

PATIENT ACTIVATION

ACROMEGALY REALITY
Disease education campaign to raise awareness of the lived realities of acromegaly and support earlier recognition and diagnosis

CrinetiCARE
Comprehensive patient support services to assist with access, adherence, and personalized care throughout the treatment journey

PATIENT ADVOCACY
Strengthening patient engagement through events, surveys, and toolkits designed to elevate the patient voice and build community



Crinetics Pharmaceuticals

Compelling Value Proposition for Paltusotine

Faster Disease Control
Titration to optimal level in weeks

Reduce Treatment Burden
Injectable SRLs difficult to administer

Maintain Symptom Control
Limit breakthrough symptoms

Improve Patient Adherence
Once-daily oral dosing

Wendy
Acromegaly Patient

PALSONIFY (paltusotine) is an investigational compound that is currently under review by the FDA and other health authorities. It has not been approved, and its safety and effectiveness have not been established.

Crinetics Pharmaceuticals

Continued Value Creation with Deep Pipeline of Transformative Drug Candidates

Program	Discovery	IND-Enabling	Phase 1	Phase 2	Phase 3	Registration	Upcoming Milestones
Paltusotine (SST2 agonist)	PATHFNDR: Acromegaly (US)						PDUFA Date (September 2025)
	pathfndr2: Acromegaly (EU)						CHMP Opinion (1H 2026)
	CAREFNDR: Carcinoid syndrome						Phase 3 (2H 2025)
Atumelnant (ACTH antagonist)	Calm-CAH: Congenital adrenal hyperplasia (adult)						Phase 3 in Adult (2H 2025)
	Balance-CAH: Congenital adrenal hyperplasia (pediatric)						Phase 2/3 in Pediatric (2H 2025)
	ACTH dependent Cushing's syndrome						Phase 2/3 (1H 2026)
Nonpeptide drug conjugate (CRN09682)	NETs and SST2-expressing solid tumors						Phase 1/2
TSH antagonist	Graves' disease (hyperthyroidism and TED)						IND
SST3 agonist	ADPKD						IND
PTH antagonist	Hyperparathyroidism						IND
Oral GLP-1 nonpeptide	Obesity						Candidate Selection
Oral GIP nonpeptide	Obesity						Candidate Selection

Partners

- SANWA KAGAKU KENKYUSHO CO., LTD. (SKK): Japan Development and Commercialization Partner for Paltusotine
- Radionetics Oncology: Licensee of targeted, nonpeptide radiopharmaceuticals
- loyal: Licensee of CRN01941 for veterinary use

SST: somatostatin receptor type; ACTH: adrenocorticotropic hormone; NETs: Neuroendocrine tumors; TSH: thyroid-stimulating hormone; TED: thyroid eye disease; ADPKD: Autosomal dominant polycystic kidney disease; PTH: parathyroid hormone; GLP-1: glucagon-like peptide-1 receptor agonists; GIP: gastric inhibitory polypeptide; IND: Investigational New Drug Application; PDUFA: Prescription Drug User Fee Act; CHMP: Committee for Medicinal Products for Human Use

Establishing Uncompromising CAH Treatment Goals

Androgen and GC Normalization

Establishing the uncompromising treatment goal of normal adrenal androgens (A4 ≤ULN) with physiologic glucocorticoid replacement

GC as Replacement, Not Treatment

Early and extended period for **glucocorticoid reduction** designed to achieve physiologic GC doses with the intent to **replace missing cortisol rather than to treat CAH**

Tailored Therapy

GC reduction periods and **PD guided dose escalation** (80 to 120 mg in the adult Phase 3 study) allows treatment to be tailored to the individual patient's needs

Broad Patient Population

Inclusive of patients who can benefit from either androgen normalization, GC normalization or both

Clinical Outcomes

New disease-specific patient-reported outcomes tool (CAHSIS PRO*) and inclusion of metabolic parameters and other **signs and symptoms of CAH** (menses, BMI, blood pressure, glucose, lipids, bone density, polycythemia, etc.)

* Exploratory
Atumelnant is an investigational drug in clinical studies. Its safety and efficacy have not been established.
A4: Androstenedione; ULN: Upper limit of normal; PD: Pharmacodynamic; GC: Glucocorticoid; BMI: Body mass index; PRO: Patient-reported outcomes; BMI: body mass index

Crinetics Pharmaceuticals

Global Phase 2/3 Pediatric CAH Trial Designed to Assess Normalization of Androgens and Glucocorticoids

Balance-CAH

Operationally Seamless Phase 2/3 Study Design

Part A (Phase 2)	Part B (Phase 3)
• Open-label, semi-sequential cohorts	• Double-blind, Placebo controlled
• Dose Determination for Part B	• Confirmatory
• 8 Week Safety and Efficacy	• 28 Week Safety and Efficacy
• PK/PD	• PK/PD

Part C (OLE)
• Open Label Extension for Part A and Part B
• Up to 5 years (average between 3-4 years)
• Long-term Safety and Efficacy
• Part A participants will start with a GC tapering

Crinetics Pharmaceuticals

Financial Results

(in millions)	Three Months Ended	
	June 30, 2025	**March 31, 2025**
Revenues	**$ 1.0**	**$ 0.4**
R&D Expenses	(80.3)	(76.2)
SG&A Expenses	(49.8)	(35.5)
Net Loss	**$ (115.6)**	**$ (96.8)**

Common Stock Outstanding of **94.2 Million** as of 7/29/2025

Fully Diluted Share Count of **111.9 Million** as of 7/29/2025

Crinetics Pharmaceuticals

$1.2 Billion Cash Balance Funds Current Operating Plan into 2029

$1.2 Billion

Cash, cash equivalents, & investments as of June 30, 2025

Into 2029

Cash runway based on current operating plan

$340 Million - $370 Million

2025 operating cash burn guidance

Supports Strategic Initiatives Including:

- Anticipated launch of paltusotine and commercial infrastructure build
- Pipeline programs and innovation from discovery
- Optionality to prioritize or pursue opportunities to enhance value across our portfolio

Crinetics Pharmaceuticals

Building the Premier, Endocrine-Rooted Pharmaceutical Company

First anticipated commercial **launch** this year

Deep pipeline with **2** late-stage programs in **4** indications

World-class R&D capabilities, **4** candidates in preclinical

IP rights into 2040s

$1.2B of cash, cash equivalents & investments

Extensive internal **endocrinology expertise**

Corporate dedication to **patients** and **science**

Crinetics Pharmaceuticals

THANK YOU

Crinetics Pharmaceuticals